Erlotinib Hydrochloride Tablet, Film Coated
Product Images NDC 46708-565

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Erlotinib Hydrochloride (NDC 46708-565). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Erlotinib 100)

Label for Erlotinib Tablets 100 mg by Alembic Pharmaceuticals Limited. The label states the container holds 30 film-coated tablets, each containing 100 mg erlotinib free base. It includes storage instructions at 25°C with permitted excursions and notes child-resistant packaging. The label features an NDC number 46708-566-30 and a barcode.*

FDA Label Image

30 Tablets (Erlotinib 150)

Label for Erlotinib Tablets 150 mg, film-coated oral tablets by Alembic Pharmaceuticals Limited. The label states the dosage strength, quantity of 30 tablets, and includes storage instructions. It also displays the NDC number 46708-567-30 and manufacturing location in Gujarat, India.*

FDA Label Image

30 Tablets (Erlotinib 25)

Label for Erlotinib Tablets 25 mg, film-coated oral tablets. The label states each tablet contains 25 mg erlotinib free base, with a package count of 30 tablets. Manufactured by Alembic Pharmaceuticals Limited, the label includes storage instructions and a barcode with the NDC 46708-565-30.*

FDA Label Image

Figure1 (Erlotinib Figure1)

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months, comparing two groups labeled Chemotherapy and Erlotinib. The x-axis represents duration in months, and the y-axis shows survival probability from 0 to 1. Below the chart, the number of patients at risk at various time points is listed for both groups.*

FDA Label Image

Figure 2 (Erlotinib Figure2)

A Kaplan-Meier survival probability plot showing overall survival over time in months for two groups: placebo and erlotinib. The y-axis represents survival probability from 0 to 1, and the x-axis represents overall survival time in months up to 36. The graph compares the survival curves of patients receiving placebo versus erlotinib, with the number of patients at risk listed below for each time point.*

FDA Label Image

Figure 3 (Erlotinib Figure3)

A survival probability Kaplan-Meier curve comparing overall survival in months between patients treated with Erlotinib and placebo. The graph shows two survival curves over a 27-month period, with a table below indicating the number of patients at risk in each group at various time points.*

FDA Label Image

Figure4 (Erlotinib Figure4)

A Kaplan-Meier survival curve showing overall survival probability over time in months for two patient groups: one receiving erlotinib and a placebo group. The chart includes a table below indicating the number of patients at risk at various time points for both groups.*

FDA Label Image

Structure (Erlotinib Str2)

Chemical structure of Erlotinib Hydrochloride, a small molecule active ingredient shown with its characteristic fused ring system, alkyne group, and hydrochloride salt representation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.